Anthracen-9-yl-[3-(morpholine-4-sulfonyl)-[1,4']bipiperidinyl-1'-yl]-methanone | 591780-30-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: Anthracen-9-yl-[3-(morpholine-4-sulfonyl)-[1,4']bipiperidinyl-1'-yl]-methanone
• 英文别名: Anthracen-9-yl-[4-(3-morpholin-4-ylsulfonylpiperidin-1-yl)piperidin-1-yl]methanone
• CAS: 591780-30-2
• 化学式: C₂₉H₃₅N₃O₄S
• 分子量: 521.681
• InChiKey: RQUXGJBGJXVBRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  37
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  78.5
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Acetyl-CoA carboxylase inhibitors
  申请人：Pfizer Inc.

  公开号：US20030187254A1

  公开（公告）日：2003-10-02

  Acetyl Coenzyme A Carboxylase inhibitors, pharmaceutical compositions containing such compounds and the use of such compounds to treat for example, Metabolic Syndrome including atherosclerosis, diabetes and obesity.

  乙酰辅酶A羧化酶抑制剂，含有此类化合物的药物组合物，以及使用此类化合物治疗代谢综合征，包括动脉粥样硬化、糖尿病和肥胖等疾病。
• [EN] ACC INHIBITORS<br/>[FR] INHIBITEURS DE L'ACETYL-COA-CARBOXYLASE
  申请人：PFIZER PROD INC

  公开号：WO2003072197A1

  公开（公告）日：2003-09-04

  Acetyl Coenzyme A Carboxylase inhibitors of formula (1), pharmaceutical compositions containing such compounds and the use of such compounds to treat for example, Metabolic Syndrome including atherosclerosis, diabetes and obesity.

  Acetyl辅酶A羧化酶抑制剂的化学式（1），含有这些化合物的药物组合物以及使用这些化合物治疗代谢综合症，包括动脉粥样硬化，糖尿病和肥胖症的用途。
• ACC INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1478437A1

  公开（公告）日：2004-11-24
• INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM
  申请人：Neuera Pharmaceuticals, Inc.

  公开号：EP2150265A1

  公开（公告）日：2010-02-10
• Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism
  申请人：Henderson Samuel T.

  公开号：US20110003767A1

  公开（公告）日：2011-01-06

  This invention relates to methods of using inhibitors of the enzyme acetyl-CoA carboxylase (ACC) for the treatment, prevention, inhibition or alleviation of diseases associated with neuronal hypometabolism and/or loss of cognitive function caused by reduced neuronal metabolism such as, for example, Age Associated Memory Impairment (AAMI), Mild Cognitive Impairment (MCI), Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia induced memory loss, Huntington's disease and many others.